Sign In
Buy NRXP
$4.05
-0.570 (-12.34%)
At Close: Jun 03, 2026
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
08:30am, Monday, 15'th Apr 2024
Formulation based on prior patents by NRx founder Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration Company expects Compositi
Data transferred for independent statistical analysis Top-line data expected in April 2024 RADNOR, Pa. , April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals",
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
01:02pm, Thursday, 04'th Apr 2024
NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for April 4th
07:51am, Thursday, 04'th Apr 2024
DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
03:08pm, Monday, 01'st Apr 2024
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
08:28am, Monday, 01'st Apr 2024
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend -- 50% reduction in corporate overhead and 25% reduction in overall net loss
Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
08:00am, Thursday, 28'th Mar 2024
Common Stock Will Begin Trading on Split-Adjusted Basis on April 2, 2024 RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"),
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
04:02pm, Thursday, 21'st Mar 2024
RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will re
Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today?
08:31am, Tuesday, 27'th Feb 2024
NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Tuesday after the clinical-stage pharmaceutical company announced a proposed public offering for its shares. We still don't know the finer deta
The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more t
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
11:18am, Friday, 22'nd Dec 2023
We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.
5 Biotech stocks tapping into unmet mental health treatment needs
09:01am, Wednesday, 20'th Dec 2023
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giv
3 Penny Stocks Under $3 To Watch Right Now
02:22pm, Tuesday, 19'th Dec 2023
As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk.
NRX Pharmaceuticals, Inc. (NRXP) Q3 2023 Earnings Call Transcript
07:35pm, Tuesday, 14'th Nov 2023
NRX Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Stephen Willard - Chief Executive Off
